查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1981389

乳癌篩檢市場：按技術、年齡層、實施方法和最終用戶分類－2026-2032年全球市場預測

Breast Cancer Screening Market by Technology, Age Group, Delivery Mode, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，乳癌篩檢市場價值將達到 56.9 億美元，到 2026 年將成長至 60.9 億美元，到 2032 年將達到 97.5 億美元，複合年成長率為 8.00%。

主要市場統計數據
基準年 2025 56.9億美元
預計年份：2026年 60.9億美元
預測年份 2032 97.5億美元
複合年成長率 (%) 8.00%

乳癌篩檢範式演變的全面概述，重點關注技術、政策、臨床實踐和以患者為中心的就醫趨勢。

乳癌篩檢處於技術創新、臨床指南、政策改革和不斷變化的患者期​​望的交匯點，形成了一個動態環境，需要準確、循證的決策。影像技術、軟體分析和醫療服務模式的進步正在重塑臨床醫生檢測和管理早期疾病的方式。同時，法律規範和保險公司的優先事項也與關注價值、治療結果和公平獲取醫療服務的目標一致。此外，不斷發展的宣傳宣傳活動和風險分層方法也推動了對更靈敏、更微創、更人性化的篩檢途徑的需求日益成長。

一項突破性的變革，加速了利用先進影像診斷、人工智慧整合、個人化篩檢路徑和分散式雲端技術的護理模式的臨床實施。

近年來，臨床實踐和市場動態發生了一系列變革性變化，重新定義了有效且公平的乳癌篩檢。其中最顯著的變化之一是容積成像和斷層成像技術的快速臨床應用。結合先進的後處理和解讀流程，這些技術顯著提高了病灶的可見性，並降低了複查率。影像技術的進步與人工智慧 (AI) 和機器學習演算法的成熟相輔相成，這些技術能夠提昇放射科醫師的診療水平，簡化分流流程，並最佳化分散式網路中有限診斷資源的分配。

2025 年美國實施的關稅對採購、製造地、供應鏈韌性和軟體主導的臨床連續性的累積影響。

美國2025年實施的關稅政策產生了一系列累積效應，波及整個乳癌篩檢價值鏈，影響籌資策略、供應商選擇、製造地和臨床部署計畫。檢測器、數位成像電子設備、專用泵浦和線圈以及整合到先進成像平台中的半導體組件等關鍵子系統的進口成本不斷上漲，迫使供應商重新評估供應鏈冗餘和組件採購。這些壓力促使一些製造商加快區域生產和供應商多元化，同時壓縮產品藍圖，並優先考慮模組級升級而非整系統更換。

實用的細分見解，闡明特定模式的趨勢、特定年齡層的路徑、交付方式的差異以及整個臨床環境中最終用戶的採用趨勢。

了解乳癌篩檢全過程中臨床價值的產生點以及推廣應用的障礙，關鍵在於掌握各個細分領域的趨勢。技術細分能夠清楚展現技術推廣應用的軌跡。2D乳房X光乳房X光攝影仍然是基本的篩檢手段，模擬和數位系統都仍在運作，但3D合成技術的應用正在不斷增加，以提高在複雜乳房解剖結構中的檢測精度。磁振造影（MRI）技術持續發展，根據患者的風險狀況和臨床適應症，造影增強通訊協定和非造影技術均被採用。分子乳房影像技術，包括乳房特異性伽瑪成像和核子乳房攝影超音波發揮不同的作用，自動化超音波平台和攜帶式設備可用於互補的診斷目的，並擴大了門診和社區醫療機構的診療範圍。

對美洲、歐洲、中東和非洲以及亞太地區部署模式、還款環境和准入策略差異的關鍵區域見解。

區域差異正在影響乳癌篩檢的技術應用、報銷方式、人才引進以及醫療系統採用的營運模式。在美洲，尤其注重將先進的篩檢能力整合到綜合醫療網路和大規模診斷連鎖機構中，同時，人們也越來越關注人工智慧驅動的影像解讀平台，以管理龐大的患者群體並最佳化複檢率。該地區的市場動態受到支付方模式的影響，這些模式獎勵可驗證的結果，而密集型腫瘤治療計畫則推動了對高風險族群高靈敏度檢測方式的需求。

透過雲端服務模式，從企業層面深入了解整合、模組化升級、臨床證據產生和差異化。

乳癌篩檢生態系統的競爭格局呈現出參與者多元化的特點，包括影像設備製造商、專業軟體供應商、雲端服務供應商、託管服務公司和臨床服務網路。業界領導企業者透過整合硬體效能和進階分析、提供強大的臨床證據包以及降低整體擁有成本 (TCO) 的全生命週期服務能力來脫穎而出。醫療設備製造商與軟體創新者之間的策略合作已被證明是加速人工智慧功能上市和透過合作研究彌合臨床有效性差距的有效途徑。

為產業領導者提供切實可行的建議，以加速採用、增強韌性，並向臨床和支付方利害關係人展示價值。

產業領導者若想在乳癌篩檢領域維持並擴大自身地位，應採取一系列切實可行的、以證據為基礎的行動，使商業性目標與臨床優先事項和營運實際情況相符。首先，應優先進行前瞻性、多中心且符合支付方要求的臨床研究，以強力的數據支持產品聲明，證明其診斷效能、工作流程效率和後續臨床影響。其次，應採用模組化產品和商業策略，使醫療服務供應商能夠逐步升級軟體分​​析、人工智慧模組和雲端服務等功能，而無需完全更換成像系統。這有助於降低採用門檻，並維護客戶關係。

採用嚴格的混合方法調查方法，結合第二手資料、相關人員檢驗和三角驗證，對臨床和商業性研究結果檢驗。

本分析的調查方法結合了定性和定量方法，以確保所得出的洞見具有穩健性、可重複性，並能為整個生態系統中的決策者提供參考。該方法首先進行全面的二手研究，參考同行評審文獻、臨床指南、監管文件、專利趨勢和企業資訊披露，構建背景基礎並識別關鍵的技術、監管和報銷趨勢。隨後進行一手研究，包括與放射科醫生、醫院採購負責人、診斷中心管理人員、技術供應商、保險公司和臨床研究人員等各類相關人員者進行結構化訪談和討論，以檢驗假設、識別應用促進因素並突出運營限制。

最終的綜合分析將結合技術、臨床和策略要求，指導相關人員在篩檢實施和改善可及性方面取得顯著成果。

總之，在技術進步、數據驅動型解決方案的興起以及強調個人化醫療和可衡量結果的臨床範式不斷演進的推動下，乳癌篩檢正在經歷重大變革時期。高通量成像、人工智慧驅動的分析、多樣化的服務模式以及對實證醫學日益成長的期望，共同為價值鏈上的各相關人員創造了機會和挑戰。專注於模組化、實證解決方案並投資於人才培養和供應鏈韌性的醫療服務提供者和供應商，將更有能力將創新轉化為早期檢測，並持續改善患者的治療效果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：乳癌篩檢市場：依技術分類

  • 2D乳房X光攝影
    • 模擬
    • 數位的
  • 3D斷層合成
  • 磁振造影
    • 造影的使用
    • 未使用造影
  • 分子乳房影像
    • 乳腺特異性伽馬射線成像
    • 閃爍乳房X光攝影
  • 熱成像
  • 超音波
    • 自動的
    • 攜帶式的

第9章：乳癌篩檢市場：依年齡層別分類

  • 40-49歲
  • 50-69歲
  • 70歲以上
  • 40歲以下

第10章：乳癌篩檢市場：依提供方式分類

  • 雲
    • SaaS（Software as a Service）
    • 基於網路的
  • 現場

第11章：乳癌篩檢市場：依最終用戶分類

  • 門診部
  • 診所
    • 基層醫療診所
    • 專科診所
  • 診斷中心
    • 連鎖中心
    • 獨立中心
  • 醫院
    • 私立醫院
    • 公立醫院

第12章乳癌篩檢市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章乳癌篩檢市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章乳癌篩檢市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國乳癌篩檢市場

第16章：中國乳癌篩檢市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Canon Medical Systems Corporation
  • Carestream Health, Inc.
  • Fujifilm Holdings Corporation
  • GE HealthCare
  • Hologic, Inc.
  • Konica Minolta, Inc.
  • Koninklijke Philips NV
  • NanoString Technologies, Inc.
  • NIRAMAI Health Analytix Private Limited
  • Novartis AG
  • Oncocyte Corporation
  • OncoStem Diagnostics Pvt. Ltd
  • Pfizer Inc.
  • Prelude Corporation
  • Quest Diagnostics Incorporated
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Shimadzu Corporation
  • Siemens Healthineers AG
  • Syantra Inc.
  • Vayyar Imaging, Ltd.
Product Code: MRR-521BAA36EB3C

The Breast Cancer Screening Market was valued at USD 5.69 billion in 2025 and is projected to grow to USD 6.09 billion in 2026, with a CAGR of 8.00%, reaching USD 9.75 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.69 billion
Estimated Year [2026] USD 6.09 billion
Forecast Year [2032] USD 9.75 billion
CAGR (%) 8.00%

Comprehensive introduction to evolving breast cancer screening paradigms highlighting technology, policy, clinical practice and patient-centric access dynamics

Breast cancer screening is at the intersection of technological innovation, clinical guidelines, policy reform, and shifting patient expectations, creating a dynamic environment that demands precise, evidence-based decision making. Advances in imaging modalities, software analytics, and care delivery models are reshaping how clinicians detect and manage early-stage disease, while regulatory frameworks and payer priorities are aligning to emphasize value, outcomes, and equitable access. Concurrently, evolving awareness campaigns and risk-stratified approaches have intensified demand for more sensitive, less invasive, and patient-friendly screening pathways.

Against this backdrop, the ecosystem that supports screening-manufacturers, hospital systems, ambulatory centers, diagnostic chains, software vendors, and payers-must reconcile competing pressures: the need to adopt high-performance technologies that improve diagnostic accuracy, the imperative to control costs and integrate with electronic workflows, and the requirement to demonstrate clinical utility and workforce readiness. Technological convergence, including the integration of advanced image reconstruction, multiplanar visualization, and intelligent algorithms, is accelerating the clinical uptake of modalities that were once confined to tertiary centers. Meanwhile, cloud-enabled delivery modes and software-as-a-service options are lowering barriers to deployment of advanced analytics and facilitating remote reading and second-opinion workflows.

The introduction sets the stage for a detailed exploration of transformational shifts, regulatory and trade headwinds, segmentation-specific dynamics, regional differentiation, competitive behavior, and pragmatic recommendations. It is designed to inform strategic planning by executives, clinical leaders, product teams, and procurement specialists seeking to position their organizations to capture clinical value, support scalable service models, and improve patient pathways without compromising on quality or compliance.

Pivotal transformative shifts accelerating clinical adoption of advanced imaging, AI integration, personalized screening pathways and distributed cloud-enabled care models

The past few years have produced a series of transformative shifts that are redefining what effective and equitable breast cancer screening looks like in clinical practice and in market dynamics. One of the most consequential shifts is the rapid clinical adoption of volumetric and tomographic imaging techniques, which when combined with sophisticated post-processing and reading workflows, have materially improved lesion conspicuity and reduced recall rates. These imaging advances are complemented by the maturation of artificial intelligence and machine learning algorithms that augment radiologist performance, streamline triage pathways, and optimize the allocation of scarce diagnostic expertise across distributed networks.

Another foundational shift is the movement toward personalized, risk-based screening pathways. Rather than one-size-fits-all intervals and modalities, screening programs are increasingly calibrated using a combination of clinical risk factors, genetic predispositions, and prior imaging history. This has catalyzed interest in adjunctive modalities for selected cohorts, including contrast-enhanced MRI for high-risk individuals and molecular imaging techniques for dense-breast populations where traditional mammography has limitations. In parallel, delivery models are evolving: cloud-enabled platforms and software-as-a-service offerings have accelerated the decentralization of advanced analytics and enabled remote interpretation, while automated and point-of-care hardware variants are expanding access in ambulatory centers and community clinics.

Workforce transformation and clinical training are also reshaping the landscape. As imaging complexity grows, so does the need for multidisciplinary collaboration, standardized reporting, and robust quality assurance programs. Regulatory emphasis on interoperability, data privacy, and evidence of clinical benefit has heightened the bar for new product adoption, incentivizing vendors to generate stronger real-world evidence and to engage payers earlier. Collectively, these shifts are creating a screening ecosystem that is more technology-driven, more patient-centric, and more focused on demonstrable outcomes than in previous eras.

Cumulative implications of United States tariffs enacted in 2025 on procurement, manufacturing footprints, supply chain resilience and software-led clinical continuity

The imposition of tariffs by the United States in 2025 has introduced a set of cumulative effects that are reverberating across the breast cancer screening value chain, influencing procurement strategies, vendor sourcing, manufacturing footprints, and clinical adoption timelines. Increased import costs for key subsystems, such as detectors, digital acquisition electronics, specialized pumps and coils, and the semiconductor components embedded in advanced imaging platforms, have pressured equipment vendors to rethink supply chain redundancy and component sourcing. These pressures have incentivized some manufacturers to accelerate regional manufacturing or supplier diversification while compressing product roadmaps to prioritize modular upgrades over full-system replacements.

Procurement decision-makers within hospitals, diagnostic centers, and ambulatory care settings have responded by extending equipment life cycles where clinically feasible and by negotiating multi-year service and upgrade agreements that can mitigate near-term capital cost inflation. At the same time, smaller and independent diagnostic operators have sought alternative delivery models, shifting demand toward cloud-based software subscriptions and managed services that reduce upfront capital exposure. The tariffs have also amplified the importance of software-driven diagnostic enhancements that can be deployed on existing hardware platforms, enabling providers to extract incremental clinical value without undertaking full equipment replacements.

Regulatory and payer stakeholders have become more attentive to the downstream implications of supply chain disruptions on access to care and the consistency of screening programs. In response, some health systems have prioritized investments in clinical training, cross-platform compatibility, and contingency stocking of critical spare parts to preserve service continuity. Finally, the macroeconomic signal sent by tariffs has affected investor and partnership behavior, prompting some vendors to reassess geographic expansion strategies and to seek manufacturing collaborations in markets with more favorable trade terms. The net effect is a reconfiguration of strategic priorities across manufacturers, service providers, and health systems that emphasizes resilience, software-led differentiation, and flexible procurement models.

Actionable segmentation insights revealing modality-specific trajectories, age-tailored pathways, delivery-mode differentiation and end-user adoption dynamics across care settings

Segment-specific dynamics are crucial for understanding where clinical value is created and where adoption friction persists across the breast cancer screening continuum. Technology segmentation reveals distinct adoption trajectories: two-dimensional mammography remains a foundational screening modality with analog and digital variants still in operation alongside the increasing uptake of three-dimensional tomosynthesis for improved detection in complex breast anatomy. Magnetic resonance imaging continues to diversify with contrast-enhanced protocols and non-contrast techniques being deployed according to patient risk profiles and clinical indications. Molecular breast imaging, including breast-specific gamma imaging and scintimammography, is gaining selective traction as an adjunct in cases of dense tissue where traditional x-ray-based modalities are challenged. Thermography and ultrasound modalities present differentiated roles; automated ultrasound platforms and handheld devices serve complementary diagnostic purposes and extend access in ambulatory and community settings.

Age group segmentation underscores the need for differentiated pathways: younger cohorts and those under forty often require diagnostic-focused imaging due to symptom-driven evaluation and genetic risk, while middle-aged groups typically represent the core screening population with modality selection influenced by breast density and prior imaging history. Older cohorts may face different trade-offs between sensitivity and the risks associated with overdiagnosis, necessitating nuanced shared decision-making processes. Delivery-mode segmentation is shaping deployment and operational models: on-premise solutions remain essential for high-throughput imaging centers and integrated hospital systems, whereas cloud-based offerings, including software-as-a-service and web-based platforms, are enabling distributed reading workflows, centralized quality control, and incremental adoption of advanced analytics without significant capital outlay. End-user segmentation highlights the different adoption drivers across care settings: ambulatory care centers, clinics-both primary care and specialty clinics-diagnostic centers, whether chain or independent, and hospitals, both public and private, each operate under distinct procurement cycles, clinical governance structures, and reimbursement environments. Understanding these segmentation layers in combination is essential for designing product strategies, clinical evidence generation plans, and go-to-market approaches that align with the needs and constraints of each stakeholder group.

Key regional insights on differentiated adoption patterns, reimbursement environments and access strategies across Americas, EMEA and Asia-Pacific

Regional differentiation influences technology adoption, reimbursement approaches, workforce availability, and the operational models that health systems deploy for breast cancer screening. In the Americas, there is a pronounced emphasis on consolidating advanced screening capabilities within integrated delivery networks and large diagnostic chains, coupled with growing interest in deploying AI-enabled reading platforms to manage high patient volumes and optimize recall rates. Market dynamics in this region are shaped by payer models that reward demonstrable outcomes and by centralized oncology programs that drive demand for high-sensitivity modalities in high-risk populations.

The Europe, Middle East & Africa region presents a heterogeneous landscape where regulatory standards, public screening program structures, and resource availability vary widely across national jurisdictions. In parts of this region, organized population-based screening programs and universal coverage models have accelerated the adoption of standardized protocols and quality assurance frameworks, while in others, infrastructure and workforce constraints have fostered innovation in portable, lower-cost modalities and tele-radiology services that bridge gaps in access.

Asia-Pacific demonstrates a blend of high-capacity tertiary centers equipped with the latest imaging platforms and rapidly expanding community-level diagnostic services that prioritize accessibility and cost-effectiveness. In several markets, public health initiatives and private sector expansion are simultaneously increasing screening uptake, which in turn has stimulated demand for cloud-enabled workflows, AI-driven triage tools, and scalable ultrasound solutions that can be deployed in both urban and semi-urban contexts. Across regions, the balance between centralized specialist services and decentralized community access will continue to shape investment priorities and partnership models.

Strategic company-level insights on differentiation through integration, modular upgradability, clinical evidence generation and cloud-enabled service models

Competitive dynamics in the breast cancer screening ecosystem are defined by a diverse set of participants spanning imaging equipment manufacturers, specialized software vendors, cloud service providers, managed service firms, and clinical service networks. Leaders are differentiating through integrated solutions that combine hardware performance with advanced analytics, robust clinical evidence packages, and lifecycle service capabilities that reduce total cost of ownership. Strategic partnerships between device manufacturers and software innovators have become an effective route to accelerate time-to-market for AI-enabled features and to bridge clinical validation gaps through collaborative studies.

Another important trend among companies is the emphasis on modularity and upgradability, which allows customers to incrementally adopt advanced capabilities while preserving existing capital investments. This approach has been particularly attractive in environments where capital budgets are constrained or where tariff-related procurement volatility has heightened the appeal of software-driven clinical improvement. Service providers and managed-read vendors are capitalizing on cloud delivery and subscription models to offer scalable reading capacity, centralized quality assurance, and performance analytics that are valuable to both large hospital networks and independent diagnostic centers.

Finally, corporate strategies are increasingly focused on demonstrating real-world clinical impact and payer-relevant outcomes. Companies that invest in prospective clinical studies, health-economic analyses, and collaborative evidence generation with leading clinical centers are better positioned to influence guideline development and payer coverage decisions. As a result, a bifurcation is emerging between firms that emphasize incremental feature improvements and those that pursue deeper clinical validation and integrated care pathways as a route to sustained differentiation.

Practical and actionable recommendations for industry leaders to accelerate adoption, build resilience, and demonstrate clinical and payer-relevant value

Industry leaders seeking to maintain and grow their positions in the breast cancer screening arena should pursue a set of pragmatic, evidence-driven actions that align commercial objectives with clinical priorities and operational realities. First, prioritize clinical evidence generation that is prospective, multi-center, and aligned to payer endpoints so that product claims are supported by robust data demonstrating diagnostic performance, workflow efficiency, and downstream clinical impact. Second, adopt a modular product and commercial strategy that enables providers to incrementally upgrade capabilities-software analytics, AI modules, and cloud services-without requiring wholesale replacement of imaging systems, thereby lowering adoption barriers and preserving customer relationships.

Third, strengthen supply chain resilience by diversifying component sourcing, exploring regional manufacturing partnerships, and developing service models that minimize downtime and ensure continuity of diagnostic services during disruptions. Fourth, invest in training and change management programs that support radiologists, technologists, and referring clinicians in integrating new modalities and AI-assisted workflows; such investments accelerate adoption, improve diagnostic consistency, and enhance patient satisfaction. Fifth, actively engage with regulatory bodies, guideline committees, and payers to communicate real-world evidence and to shape reimbursement paradigms that reward value and outcomes rather than procedural volume. Sixth, pursue strategic collaborations across the ecosystem-academic centers, specialty clinics, chains of diagnostic centers, and technology partners-to co-develop clinical pathways, pilot new care models, and validate value propositions in representative clinical environments. By executing on these priorities, industry leaders can reduce friction in adoption, demonstrate measurable clinical benefit, and position their offerings for sustainable uptake across diverse care settings.

Rigorous mixed-methods research methodology combining secondary evidence, stakeholder interviews and triangulation to validate clinical and commercial insights

The research methodology underpinning this analysis combines qualitative and quantitative approaches to ensure that insights are robust, replicable, and relevant to decision-makers across the ecosystem. The approach begins with comprehensive secondary research drawing from peer-reviewed literature, clinical guidelines, regulatory filings, patent landscapes, and company disclosures to build a contextual foundation and identify key technology, regulatory, and reimbursement trends. This is followed by primary research, including structured interviews and consultations with a cross-section of stakeholders such as radiologists, hospital procurement officers, diagnostic center managers, technology vendors, payers, and clinical investigators, to validate assumptions, uncover adoption drivers, and surface operational constraints.

Data triangulation is applied to reconcile diverse inputs and to ensure internal consistency; clinical claims and product capabilities are cross-referenced with published studies and expert commentary. Segmentation frameworks are developed and iteratively refined through stakeholder validation to reflect real-world decision processes across technology, age cohorts, delivery modes, and end-user types. Quality assurance includes methodological audits, peer review by subject-matter experts, and sensitivity checks on key qualitative inferences. Finally, findings are synthesized into actionable narratives and strategic imperatives that are designed to support procurement decisions, product development roadmaps, clinical adoption strategies, and policy engagement initiatives.

Concluding synthesis that integrates technological, clinical and strategic imperatives to guide stakeholders toward impactful screening adoption and access improvements

In conclusion, breast cancer screening is undergoing a period of substantive transformation driven by technological advancement, the ascendancy of data-driven solutions, and evolving clinical paradigms that emphasize personalized care and measurable outcomes. The confluence of volumetric imaging, AI-enabled analytics, diversified delivery models, and increasingly sophisticated evidence expectations has created both opportunities and challenges for stakeholders across the value chain. Providers and vendors that align around modular, evidence-backed solutions and invest in workforce readiness and supply chain resilience will be best positioned to translate innovation into sustained improvements in early detection and patient outcomes.

Looking forward, the strategic focus should remain on integrating new capabilities within existing clinical workflows, demonstrating comparative clinical value in relevant patient cohorts, and crafting procurement and reimbursement narratives that reflect long-term outcomes and system-level efficiencies. By prioritizing these elements-clinical validation, flexible deployment, regional sensitivity, and pragmatic engagement with payers and policymakers-stakeholders can navigate trade headwinds, scale access to high-performance screening modalities, and ultimately contribute to earlier detection and better patient trajectories across diverse health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Breast Cancer Screening Market, by Technology

  • 8.1. 2D Mammography
    • 8.1.1. Analog
    • 8.1.2. Digital
  • 8.2. 3D Tomosynthesis
  • 8.3. Magnetic Resonance Imaging
    • 8.3.1. Contrast Enhanced
    • 8.3.2. Non Contrast
  • 8.4. Molecular Breast Imaging
    • 8.4.1. Breast Specific Gamma Imaging
    • 8.4.2. Scintimammography
  • 8.5. Thermography
  • 8.6. Ultrasound
    • 8.6.1. Automated
    • 8.6.2. Handheld

9. Breast Cancer Screening Market, by Age Group

  • 9.1. 40 To 49
  • 9.2. 50 To 69
  • 9.3. 70 And Above
  • 9.4. Under 40

10. Breast Cancer Screening Market, by Delivery Mode

  • 10.1. Cloud
    • 10.1.1. Software As A Service
    • 10.1.2. Web Based
  • 10.2. On Premise

11. Breast Cancer Screening Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Clinics
    • 11.2.1. Primary Care Clinics
    • 11.2.2. Specialty Clinics
  • 11.3. Diagnostic Centers
    • 11.3.1. Chain Centers
    • 11.3.2. Independent Centers
  • 11.4. Hospitals
    • 11.4.1. Private Hospitals
    • 11.4.2. Public Hospitals

12. Breast Cancer Screening Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Breast Cancer Screening Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Breast Cancer Screening Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Breast Cancer Screening Market

16. China Breast Cancer Screening Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Canon Medical Systems Corporation
  • 17.6. Carestream Health, Inc.
  • 17.7. Fujifilm Holdings Corporation
  • 17.8. GE HealthCare
  • 17.9. Hologic, Inc.
  • 17.10. Konica Minolta, Inc.
  • 17.11. Koninklijke Philips N.V.
  • 17.12. NanoString Technologies, Inc.
  • 17.13. NIRAMAI Health Analytix Private Limited
  • 17.14. Novartis AG
  • 17.15. Oncocyte Corporation
  • 17.16. OncoStem Diagnostics Pvt. Ltd
  • 17.17. Pfizer Inc.
  • 17.18. Prelude Corporation
  • 17.19. Quest Diagnostics Incorporated
  • 17.20. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 17.21. Shimadzu Corporation
  • 17.22. Siemens Healthineers AG
  • 17.23. Syantra Inc.
  • 17.24. Vayyar Imaging, Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BREAST CANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BREAST CANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BREAST CANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BREAST CANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BREAST CANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ANALOG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ANALOG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ANALOG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIGITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIGITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIGITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 3D TOMOSYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 3D TOMOSYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 3D TOMOSYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CONTRAST ENHANCED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CONTRAST ENHANCED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CONTRAST ENHANCED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY NON CONTRAST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY NON CONTRAST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY NON CONTRAST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BREAST SPECIFIC GAMMA IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BREAST SPECIFIC GAMMA IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BREAST SPECIFIC GAMMA IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SCINTIMAMMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SCINTIMAMMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SCINTIMAMMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AUTOMATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AUTOMATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AUTOMATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HANDHELD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HANDHELD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HANDHELD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 40 TO 49, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 40 TO 49, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 40 TO 49, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 50 TO 69, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 50 TO 69, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 50 TO 69, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 70 AND ABOVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 70 AND ABOVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 70 AND ABOVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY UNDER 40, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY UNDER 40, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY UNDER 40, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SOFTWARE AS A SERVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SOFTWARE AS A SERVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SOFTWARE AS A SERVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY WEB BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY WEB BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY WEB BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ON PREMISE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ON PREMISE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ON PREMISE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CHAIN CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CHAIN CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CHAIN CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY INDEPENDENT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY INDEPENDENT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY INDEPENDENT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 229. GCC BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GCC BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. GCC BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 232. GCC BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 233. GCC BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 234. GCC BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 235. GCC BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. GCC BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 237. GCC BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 238. GCC BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. GCC BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 240. GCC BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 268. G7 BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 269. G7 BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 270. G7 BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 271. G7 BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 272. G7 BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 273. G7 BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 274. G7 BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 275. G7 BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 276. G7 BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 277. G7 BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. G7 BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 279. G7 BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 280. G7 BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 281. NATO BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. NATO BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. NATO BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 284. NATO BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 285. NATO BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 286. NATO BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 287. NATO BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 288. NATO BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 289. NATO BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 290. NATO BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. NATO BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 292. NATO BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 293. NATO BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 294. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA BREAST CANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)